Bath & Body Works (NYSE:BBWI) Issues Quarterly Earnings Results

Bath & Body Works (NYSE:BBWI - Get Free Report) issued its earnings results on Thursday. The company reported $2.09 EPS for the quarter, beating the consensus estimate of $2.04 by $0.05, Zacks reports. The business had revenue of $2.79 billion for the quarter, compared to the consensus estimate of $2.78 billion. Bath & Body Works had a negative return on equity of 44.03% and a net margin of 12.43%. Bath & Body Works updated its Q1 2025 guidance to 0.360-0.430 EPS and its FY 2025 guidance to 3.250-3.600 EPS.

Bath & Body Works Stock Down 2.3 %

NYSE:BBWI traded down $0.85 during mid-day trading on Monday, reaching $35.38. The company's stock had a trading volume of 6,003,122 shares, compared to its average volume of 3,816,168. The firm has a market capitalization of $7.66 billion, a PE ratio of 8.63, a price-to-earnings-growth ratio of 0.92 and a beta of 1.83. The stock has a fifty day moving average of $37.70 and a 200-day moving average of $34.15. Bath & Body Works has a 1 year low of $26.20 and a 1 year high of $52.99.

Bath & Body Works Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 21st will be paid a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 2.26%. The ex-dividend date is Friday, February 21st. Bath & Body Works's dividend payout ratio is currently 21.98%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on BBWI shares. JPMorgan Chase & Co. set a $47.00 price target on Bath & Body Works in a report on Thursday. TD Cowen upped their target price on shares of Bath & Body Works from $42.00 to $48.00 and gave the company a "buy" rating in a research note on Thursday, December 12th. Piper Sandler raised their price target on shares of Bath & Body Works from $36.00 to $39.00 and gave the company a "neutral" rating in a report on Monday, January 6th. Morgan Stanley decreased their price objective on shares of Bath & Body Works from $51.00 to $48.00 and set an "overweight" rating for the company in a report on Thursday, November 21st. Finally, Robert W. Baird raised their target price on shares of Bath & Body Works from $45.00 to $47.00 and gave the stock an "outperform" rating in a report on Friday. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat, Bath & Body Works currently has an average rating of "Moderate Buy" and an average price target of $45.06.

Remove Ads

Bath & Body Works announced that its board has authorized a stock repurchase plan on Thursday, February 27th that permits the company to repurchase $500.00 million in shares. This repurchase authorization permits the company to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's board of directors believes its stock is undervalued.

Bath & Body Works Company Profile

Bath & Body Works, Inc is a specialty retailers and home to America's Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.